Speakers

Distinguished Co-Chairs

Lisa Dunkin

Assistant General Counsel, Litigation
Zimmer Biomet (Fort Wayne, IN)

Co-Chairs’ Welcome Remarks

December 7, 2021 • 8:15 am

Brennan Torregrossa

Senior Vice President, Head of Global Litigation
GSK (Philadelphia, PA)

Co-Chairs’ Welcome Remarks

December 7, 2021 • 8:15 am

Members of the Judiciary

Honorable Karen K. Caldwell

Chief Judge
U.S. District Court, E.D. of Kentucky
Chair
Judicial Panel on Multidistrict Litigation (JPML)

A View From the Bench – 2021 Edition: Judicial Insights on Drug and Medical Device Products Liability Litigation and How Courts Are Adjusting to the Lingering Effects of the Pandemic

December 8, 2021 • 10:30 am

Honorable William F. Highberger

Superior Court Judge
Los Angeles County Superior Court

A View From the Bench – 2021 Edition: Judicial Insights on Drug and Medical Device Products Liability Litigation and How Courts Are Adjusting to the Lingering Effects of the Pandemic

December 8, 2021 • 10:30 am

Honorable Eduardo C. Robreno

Senior Judge
U.S. District Court, E.D. Pennsylvania

A View From the Bench – 2021 Edition: Judicial Insights on Drug and Medical Device Products Liability Litigation and How Courts Are Adjusting to the Lingering Effects of the Pandemic

December 8, 2021 • 10:30 am

Honorable Nancy J. Rosenstengel

Chief District Judge
U.S. District Court, S.D. Illinois (East St. Louis, IL)

A View From the Bench – 2021 Edition: Judicial Insights on Drug and Medical Device Products Liability Litigation and How Courts Are Adjusting to the Lingering Effects of the Pandemic

December 8, 2021 • 10:30 am

Honorable John R. Tunheim

Chief Judge
U.S. District Court, D. Minnesota

A View From the Bench – 2021 Edition: Judicial Insights on Drug and Medical Device Products Liability Litigation and How Courts Are Adjusting to the Lingering Effects of the Pandemic

December 8, 2021 • 10:30 am

Law Firm Counsel

Michele Suggs Adeleye

Vice President and AGC
Pfizer (New York, NY)

A — Lessons Learned from Recent Developments in This Year’s Opioid Trials

B — Analyzing Risks and Theories of Potential Liability Associated with New Technologies, Digital Health and Artificial Intelligence

December 7, 2021 • 5:30 pm

Cindy Aribisala

Senior Counsel
Gilead Sciences, Inc. (Foster City, CA)

Keys to Effectively Defending MDLs and Navigating the Remand Process from Transfer to Trial

December 7, 2021 • 2:30 pm

Elizabeth Balakhani

Assistant General Counsel
GSK (Philadelphia, PA)

An Industry Under Attack: Addressing the Recent Rise of OTC Product Liability Litigation

December 8, 2021 • 8:45 am

Mary-Alice Barrett

Associate General Counsel
Genentech (Little Falls, NJ)

Drug and Medical Device 2021 Year in Review: How the Most Significant Product Liability Decisions of the Last Year are Impacting Your Clients and Cases

December 7, 2021 • 8:30 am

Adam Bassing

Adam Bassing

Head of Global Litigation
UCB, Inc. (Smyrna, GA)

Interactive Ethics Lab

December 8, 2021 • 2:30 pm

Eva Canaan

Partner
King & Spalding LLP (New York, NY)

A — Daubert Revisited: Examining Recent Proposed Amendments to Rule 702 and What They Could Mean for the Future of Drug and Device Litigation

B — Incorporating Key Points from the Recent NDMA Litigations Into Your Future Trial Practice (Zantac, Valsartan and Metformin)

December 7, 2021 • 4:45 pm

Lisa Dunkin

Assistant General Counsel, Litigation
Zimmer Biomet (Fort Wayne, IN)

Co-Chairs’ Welcome Remarks

December 7, 2021 • 8:15 am

Christopher M. Guth

Senior Assistant General Counsel
Bayer (Pittsburgh, PA)

A — Daubert Revisited: Examining Recent Proposed Amendments to Rule 702 and What They Could Mean for the Future of Drug and Device Litigation

B — Incorporating Key Points from the Recent NDMA Litigations Into Your Future Trial Practice (Zantac, Valsartan and Metformin)

December 7, 2021 • 4:45 pm

Max Heerman

Senior Legal Counsel, Litigation
Medtronic (Washington, DC)

A — Lessons Learned from Recent Developments in This Year’s Opioid Trials

B — Analyzing Risks and Theories of Potential Liability Associated with New Technologies, Digital Health and Artificial Intelligence

December 7, 2021 • 5:30 pm

Adrienne M. Hollander

Assistant General Counsel
American Regent Inc., a Daiichi Sankyo Group Company (Shirley, NY)

Diversity, Equity & Inclusion Town Hall: A Candid Discussion About Drivers of Successful DE&I Initiatives—What’s Working, What’s Not, and How We Can Do Better

December 8, 2021 • 1:30 pm

Donald LeGower

Assistant General Counsel - Litigation and Government Investigations
Bristol-Myers Squibb (Lawrenceville, NJ)

Drug and Medical Device 2021 Year in Review: How the Most Significant Product Liability Decisions of the Last Year are Impacting Your Clients and Cases

December 7, 2021 • 8:30 am

Sarah Padgitt

Associate General Counsel
Baxter (Chicago, IL)

Drug and Medical Device 2021 Year in Review: How the Most Significant Product Liability Decisions of the Last Year are Impacting Your Clients and Cases

December 7, 2021 • 8:30 am

Zane Riester

Senior Counsel
Johnson & Johnson (New Brunswick, NJ)

Keys to Effectively Defending MDLs and Navigating the Remand Process from Transfer to Trial

December 7, 2021 • 2:30 pm

Eric Santoro

Senior Counsel, Global Litigation
AstraZeneca (Philadelphia, PA)

Drug and Medical Device 2021 Year in Review: How the Most Significant Product Liability Decisions of the Last Year are Impacting Your Clients and Cases

December 7, 2021 • 8:30 am

Jason Steinhart

Associate Vice President
Associate General Counsel, North American Litigation
Sanofi (Bridgewater, NJ)

Navigating the New Hybrid World of Virtual/In-Person Trial Practice: Managing Shifting Client and Court Expectations and Implementing Strategies for Successful Outcomes

December 7, 2021 • 9:30 am

Brennan Torregrossa

Senior Vice President, Head of Global Litigation
GSK (Philadelphia, PA)

Co-Chairs’ Welcome Remarks

December 7, 2021 • 8:15 am

Justin Witzmann

Senior Litigation Counsel
Nuvasive (San Diego, CA)

Navigating the New Hybrid World of Virtual/In-Person Trial Practice: Managing Shifting Client and Court Expectations and Implementing Strategies for Successful Outcomes

December 7, 2021 • 9:30 am

Esteemed Faculty

Stacy Cline Amin

Stacy Amin

Partner
Co-Chair, FDA Regulatory & Compliance Practice
Morrison & Foerster LLP
Former Chief Counsel, Food and Drug Administration, 2018-2021 (Washington, DC)

FDA Think Tank: Examining the Latest FDA Initiatives Influencing the Products Liability Sphere

December 7, 2021 • 11:00 am

Andrew T. (Andy) Bayman

Partner
King & Spalding LLP (Atlanta, GA)

A View From the Bench – 2021 Edition: Judicial Insights on Drug and Medical Device Products Liability Litigation and How Courts Are Adjusting to the Lingering Effects of the Pandemic

December 8, 2021 • 10:30 am

James M. Beck

Senior Life Sciences Policy Analyst
Reed Smith LLP (Philadelphia, PA)

Creating a Roadmap for Post-Albrecht Preemption Using Takeaways from This Year’s Most Significant Rulings

December 7, 2021 • 4:00 pm

Erin Bosman

Partner, Co-Chair of Class Actions and Mass Torts Practice Group
Morrison & Foerster LLP (San Diego, CA)

Navigating the New Hybrid World of Virtual/In-Person Trial Practice: Managing Shifting Client and Court Expectations and Implementing Strategies for Successful Outcomes

December 7, 2021 • 9:30 am

Kim Bueno

Attorney
Butler Snow LLP (Austin, TX)

Navigating the New Hybrid World of Virtual/In-Person Trial Practice: Managing Shifting Client and Court Expectations and Implementing Strategies for Successful Outcomes

December 7, 2021 • 9:30 am

Robert Charrow

Shareholder
Greenberg Traurig LLP
Recent Former General Counsel, U.S. Department of Health & Human Services (HHS) (Washington, DC)

Spotlight Speaker

December 8, 2021 • 10:00 am

Lori Cohen

Law Firm Vice Chair
Co-Chair, Global Litigation Practice
Greenberg Traurig LLP (Atlanta, GA)

Drug and Medical Device 2021 Year in Review: How the Most Significant Product Liability Decisions of the Last Year are Impacting Your Clients and Cases

December 7, 2021 • 8:30 am

Paul J. (PJ) Cosgrove

Partner | Co-Group Leader, Product Liability
Ulmer & Berne LLP (Cincinnati, OH)

A — Daubert Revisited: Examining Recent Proposed Amendments to Rule 702 and What They Could Mean for the Future of Drug and Device Litigation

B — Incorporating Key Points from the Recent NDMA Litigations Into Your Future Trial Practice (Zantac, Valsartan and Metformin)

December 7, 2021 • 4:45 pm

D’Lesli M. Davis

Partner
Norton Rose Fulbright US LLP (Dallas, TX)

Keys to Effectively Defending MDLs and Navigating the Remand Process from Transfer to Trial

December 7, 2021 • 2:30 pm

Marcella Ducca

Co-Chair, Atlanta Products Liability Litigation Group
Greenberg Traurig LLP (Atlanta, GA)

Keys to Effectively Defending MDLs and Navigating the Remand Process from Transfer to Trial

December 7, 2021 • 2:30 pm

Shankar Duraiswamy

Partner
Covington & Burling LLP (Washington, DC)

A — Lessons Learned from Recent Developments in This Year’s Opioid Trials

B — Analyzing Risks and Theories of Potential Liability Associated with New Technologies, Digital Health and Artificial Intelligence

December 7, 2021 • 5:30 pm

Sandra A. Edwards

Co-Chair, Product Liability & Mass Torts Practice
Winston & Strawn LLP (San Francisco, CA)

An Industry Under Attack: Addressing the Recent Rise of OTC Product Liability Litigation

December 8, 2021 • 8:45 am

Ilana H. Eisenstein

Partner
DLA Piper (Philadelphia, PA)

Creating a Roadmap for Post-Albrecht Preemption Using Takeaways from This Year’s Most Significant Rulings

December 7, 2021 • 4:00 pm

Sean P. Fahey

Partner
Troutman Pepper (Philadelphia, PA)

Taking Down the Rising Behemoth: Combatting Plaintiff Tactics That Are Transforming MDLs Into the Machines We See Today

December 7, 2021 • 1:00 pm

Aileen Fair

Senior Corporate Counsel, Litigation & Government Investigations
Bristol Myers Squibb (Princeton, NJ)

Interactive Ethics Lab

December 8, 2021 • 2:30 pm

Wendy West Feinstein

Partner
Morgan, Lewis & Bockius LLP (Pittsburgh, PA)

A — Lessons Learned from Recent Developments in This Year’s Opioid Trials

B — Analyzing Risks and Theories of Potential Liability Associated with New Technologies, Digital Health and Artificial Intelligence

December 7, 2021 • 5:30 pm

John Galvin

Partner
Thompson Coburn LLP (St. Louis, Missouri)

Taking Down the Rising Behemoth: Combatting Plaintiff Tactics That Are Transforming MDLs Into the Machines We See Today

December 7, 2021 • 1:00 pm

Andrew D. Kaplan

Partner
Crowell & Moring LLP (Washington, DC)

Taking Down the Rising Behemoth: Combatting Plaintiff Tactics That Are Transforming MDLs Into the Machines We See Today

December 7, 2021 • 1:00 pm

Kristin M. Kaplan

Of Counsel
Shook Hardy & Bacon LLP (Kansas City, MO)

FDA Think Tank: Examining the Latest FDA Initiatives Influencing the Products Liability Sphere

December 7, 2021 • 11:00 am

John P. Lavelle Jr.

Partner
Morgan Lewis & Bockius LLP (Philadelphia, PA)

A — Daubert Revisited: Examining Recent Proposed Amendments to Rule 702 and What They Could Mean for the Future of Drug and Device Litigation

B — Incorporating Key Points from the Recent NDMA Litigations Into Your Future Trial Practice (Zantac, Valsartan and Metformin)

December 7, 2021 • 4:45 pm

John Lewis, Jr.

Partner
Shook Hardy & Bacon LLP (Houston, TX)

Diversity, Equity & Inclusion Town Hall: A Candid Discussion About Drivers of Successful DE&I Initiatives—What’s Working, What’s Not, and How We Can Do Better

December 8, 2021 • 1:30 pm

Christina Marinakis, J.D., Psy.D.

Shareholder / Director – Jury Research
Litigation Insights (Los Angeles, CA)

Assessing How the COVID-19 Pandemic is Impacting Juror Mindsets, Perceptions and Verdicts: What is the Data Showing?

December 8, 2021 • 11:45 am

Mitch Morinec

Shareholder
Segal McCambridge Singer & Mahoney (Chicago, IL)

Creating a Roadmap for Post-Albrecht Preemption Using Takeaways from This Year’s Most Significant Rulings

December 7, 2021 • 4:00 pm

Tariq M. Naeem

Partner
Tucker Ellis LLP (Cleveland, OH)

A — Lessons Learned from Recent Developments in This Year’s Opioid Trials

B — Analyzing Risks and Theories of Potential Liability Associated with New Technologies, Digital Health and Artificial Intelligence

December 7, 2021 • 5:30 pm

Julie Park

Partner
Morrison & Foerster LLP (San Diego, CA)

FDA Think Tank: Examining the Latest FDA Initiatives Influencing the Products Liability Sphere

December 7, 2021 • 11:00 am

Maithilee K. Pathak, PhD JD

Partner
R&D Strategic Solutions (Cumming GA)

Assessing How the COVID-19 Pandemic is Impacting Juror Mindsets, Perceptions and Verdicts: What is the Data Showing?

December 8, 2021 • 11:45 am

Andrea Roberts Pierson

Partner
Faegre Drinker Biddle & Reath LLP

Keys to Effectively Defending MDLs and Navigating the Remand Process from Transfer to Trial

December 7, 2021 • 2:30 pm

Lyn Pruitt

Partner
DLA Piper (Dallas, TX)

Assessing How the COVID-19 Pandemic is Impacting Juror Mindsets, Perceptions and Verdicts: What is the Data Showing?

December 8, 2021 • 11:45 am

Kristen L. Richer

Partner
Barnes & Thornburg LLP (Los Angeles, CA)

An Industry Under Attack: Addressing the Recent Rise of OTC Product Liability Litigation

December 8, 2021 • 8:45 am

Susan Sharko

Partner
Faegre Drinker Biddle & Reath LLP (Florham Park, NJ)

Taking Down the Rising Behemoth: Combatting Plaintiff Tactics That Are Transforming MDLs Into the Machines We See Today

December 7, 2021 • 1:00 pm

Erik Snapp

Partner
Dechert LLP (Chicago, IL)

A — Daubert Revisited: Examining Recent Proposed Amendments to Rule 702 and What They Could Mean for the Future of Drug and Device Litigation

B — Incorporating Key Points from the Recent NDMA Litigations Into Your Future Trial Practice (Zantac, Valsartan and Metformin)

December 7, 2021 • 4:45 pm

Danielle Gentin Stock

Counsel
Dechert LLP (New York, NY)

A — Lessons Learned from Recent Developments in This Year’s Opioid Trials

B — Analyzing Risks and Theories of Potential Liability Associated with New Technologies, Digital Health and Artificial Intelligence

December 7, 2021 • 5:30 pm

Emily Ullman

Partner
Covington & Burling LLP (Washington, DC)

Creating a Roadmap for Post-Albrecht Preemption Using Takeaways from This Year’s Most Significant Rulings

December 7, 2021 • 4:00 pm

Rachel Weil

Partner
Reed Smith LLP (Philadelphia, PA)

A — Daubert Revisited: Examining Recent Proposed Amendments to Rule 702 and What They Could Mean for the Future of Drug and Device Litigation

B — Incorporating Key Points from the Recent NDMA Litigations Into Your Future Trial Practice (Zantac, Valsartan and Metformin)

December 7, 2021 • 4:45 pm

Steven Weisburd

Shareholder
Carlton Fields, P.A. (Los Angeles, CA)

An Industry Under Attack: Addressing the Recent Rise of OTC Product Liability Litigation

December 8, 2021 • 8:45 am

Meredith Thornburgh White

Partner
Barnes & Thornburg LLP (Indianapolis, IN)

Navigating the New Hybrid World of Virtual/In-Person Trial Practice: Managing Shifting Client and Court Expectations and Implementing Strategies for Successful Outcomes

December 7, 2021 • 9:30 am

Rebecca K. Wood

Partner
Global Life Sciences Leadership Council
Sidley Austin LLP
Former Chief Counsel, Food and Drug Administration (FDA) (Washington, DC)

FDA Think Tank: Examining the Latest FDA Initiatives Influencing the Products Liability Sphere

December 7, 2021 • 11:00 am